Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash to Debt 91.41
NAS:IDRA's Cash to Debt is ranked higher than
53% of the 964 Companies
in the Global Biotechnology industry.

( Industry Median: 46.43 vs. NAS:IDRA: 91.41 )
Ranked among companies with meaningful Cash to Debt only.
NAS:IDRA' s Cash to Debt Range Over the Past 10 Years
Min: 0.02  Med: 965.41 Max: No Debt
Current: 91.41
Equity to Asset 0.85
NAS:IDRA's Equity to Asset is ranked higher than
76% of the 715 Companies
in the Global Biotechnology industry.

( Industry Median: 0.67 vs. NAS:IDRA: 0.85 )
Ranked among companies with meaningful Equity to Asset only.
NAS:IDRA' s Equity to Asset Range Over the Past 10 Years
Min: -1.57  Med: 0.66 Max: 0.94
Current: 0.85
-1.57
0.94
F-Score: 4
Z-Score: 1.47
M-Score: 11.43
WACC vs ROIC
23.11%
-420.82%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating margin (%) -4655.51
NAS:IDRA's Operating margin (%) is ranked lower than
89% of the 749 Companies
in the Global Biotechnology industry.

( Industry Median: -78.20 vs. NAS:IDRA: -4655.51 )
Ranked among companies with meaningful Operating margin (%) only.
NAS:IDRA' s Operating margin (%) Range Over the Past 10 Years
Min: -53084.93  Med: -10150.44 Max: 21.4
Current: -4655.51
-53084.93
21.4
Net-margin (%) -4621.03
NAS:IDRA's Net-margin (%) is ranked lower than
89% of the 749 Companies
in the Global Biotechnology industry.

( Industry Median: -75.28 vs. NAS:IDRA: -4621.03 )
Ranked among companies with meaningful Net-margin (%) only.
NAS:IDRA' s Net-margin (%) Range Over the Past 10 Years
Min: -52934.25  Med: -10091.29 Max: 21.86
Current: -4621.03
-52934.25
21.86
ROE (%) -71.14
NAS:IDRA's ROE (%) is ranked lower than
71% of the 878 Companies
in the Global Biotechnology industry.

( Industry Median: -33.45 vs. NAS:IDRA: -71.14 )
Ranked among companies with meaningful ROE (%) only.
NAS:IDRA' s ROE (%) Range Over the Past 10 Years
Min: -352.71  Med: -114.4 Max: 27.3
Current: -71.14
-352.71
27.3
ROA (%) -64.26
NAS:IDRA's ROA (%) is ranked lower than
76% of the 971 Companies
in the Global Biotechnology industry.

( Industry Median: -29.51 vs. NAS:IDRA: -64.26 )
Ranked among companies with meaningful ROA (%) only.
NAS:IDRA' s ROA (%) Range Over the Past 10 Years
Min: -105.66  Med: -66.5 Max: 14.1
Current: -64.26
-105.66
14.1
ROC (Joel Greenblatt) (%) -3046.13
NAS:IDRA's ROC (Joel Greenblatt) (%) is ranked lower than
75% of the 931 Companies
in the Global Biotechnology industry.

( Industry Median: -372.06 vs. NAS:IDRA: -3046.13 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
NAS:IDRA' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -11798.05  Med: -3162.76 Max: 467.46
Current: -3046.13
-11798.05
467.46
EBITDA Growth (3Y)(%) -16.30
NAS:IDRA's EBITDA Growth (3Y)(%) is ranked lower than
68% of the 521 Companies
in the Global Biotechnology industry.

( Industry Median: 1.50 vs. NAS:IDRA: -16.30 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
NAS:IDRA' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: -69.8  Med: -16.3 Max: 5
Current: -16.3
-69.8
5
EPS Growth (3Y)(%) -19.70
NAS:IDRA's EPS Growth (3Y)(%) is ranked lower than
67% of the 511 Companies
in the Global Biotechnology industry.

( Industry Median: -4.20 vs. NAS:IDRA: -19.70 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
NAS:IDRA' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: -62.7  Med: -21.5 Max: 4.6
Current: -19.7
-62.7
4.6
» NAS:IDRA's 10-Y Financials

Financials (Next Earnings Date: 2017-03-10)


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Guru Trades

Q4 2015

IDRA Guru Trades in Q4 2015

Jim Simons 20,050 sh (New)
Steven Cohen 1,265,100 sh (+88.65%)
Paul Tudor Jones 18,288 sh (-3.71%)
» More
Q1 2016

IDRA Guru Trades in Q1 2016

Steven Cohen Sold Out
Jim Simons Sold Out
Paul Tudor Jones 17,988 sh (-1.64%)
» More
Q2 2016

IDRA Guru Trades in Q2 2016

Paul Tudor Jones 17,988 sh (unchged)
» More
Q3 2016

IDRA Guru Trades in Q3 2016

Paul Tudor Jones 19,188 sh (+6.67%)
» More
» Details

Insider Trades

Latest Guru Trades with IDRA

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 325414    SIC: 2836
Compare:NAS:CARA, NAS:ESPR, NAS:MNKD, NAS:RXDX, NAS:ABEO, NAS:STML, OTCPK:CLVLF, NAS:ARWR, NAS:PETX, NAS:OCUL, NAS:PTI, NAS:SGMO, NYSE:KDMN, NAS:MNOV, NAS:CMRX, NAS:PRTK, NAS:MRUS, OTCPK:SPHDF, AMEX:PFNX, NAS:TGTX » details
Traded in other countries:HXXA.Germany,
Idera Pharmaceuticals Inc is a clinical stage biotechnology company. The Company is engaged in the discovery, development and commercialization of novel therapeutics for oncology and rare diseases.

Idera Pharmaceuticals Inc was incorporated in Delaware on May 25, 1989. The Company is a clinical stage biotechnology company. The Company is engaged in the discovery, development and commercialization of novel therapeutics for oncology and rare diseases. The Company uses two distinct proprietary drug discovery technology platforms to design and develop drug candidates including nucleic acid therapeutics that target biologic pathways implicated in disease processes. The Company first platform focuses on inhibiting over-activation of Toll-like receptors (TLRs) and the second is its gene silencing oligonucleotides (GSOs) platform. The Company TLR antagonist drug candidates are IMO-8400 and IMO-9200, which are both antagonists of TLR7, TLR8 and TLR9. The Company also has created compounds that are agonists of TLR3, TLR7, TLR8 and TLR9. Its TLR agonist drug candidates are IMO-2055 and IMO-2125, which are both agonists of TLR9. The Company's drug candidates include IMO-8400 an novel synthetic oligonucleotide antagonist of TLR7, TLR8, and TLR9. It is developing IMO-8400 for the treatment of certain genetically defined forms of B-cell lymphoma and for the treatment of rare diseases. It is also conducting a Phase 1 clinical trial of IMO-9200 in healthy subjects, as well as additional preclinical studies of IMO-9200 for a selected autoimmune disease. The Company relies upon third parties to produce material for nonclinical and clinical testing purposes. The Company's competitors include Dynavax, InDex Pharmaceuticals AB, Mologen AG, BioLineRx Ltd., Innate Immunotherapeutics Ltd., VentiRx Pharmaceuticals Inc., Telormedix S.A., Gilead Sciences Inc., GlaxoSmithKline plc, AstraZeneca plc and Hoffmann-La Roch. The testing, manufacturing, labeling, advertising, promotion, export, and marketing of its drug candidates are subject to regulation by governmental authorities in Europe, the United States, and elsewhere throughout the world.

Ratios

vs
industry
vs
history
P/B 4.00
IDRA's P/B is ranked lower than
53% of the 861 Companies
in the Global Biotechnology industry.

( Industry Median: 3.50 vs. IDRA: 4.00 )
Ranked among companies with meaningful P/B only.
IDRA' s P/B Range Over the Past 10 Years
Min: 1.77  Med: 5.36 Max: 391.43
Current: 4
1.77
391.43
P/S 184.28
IDRA's P/S is ranked lower than
89% of the 695 Companies
in the Global Biotechnology industry.

( Industry Median: 10.41 vs. IDRA: 184.28 )
Ranked among companies with meaningful P/S only.
IDRA' s P/S Range Over the Past 10 Years
Min: 2.57  Med: 37.66 Max: 6080
Current: 184.28
2.57
6080
Current Ratio 7.06
IDRA's Current Ratio is ranked higher than
66% of the 957 Companies
in the Global Biotechnology industry.

( Industry Median: 4.22 vs. IDRA: 7.06 )
Ranked among companies with meaningful Current Ratio only.
IDRA' s Current Ratio Range Over the Past 10 Years
Min: 0.02  Med: 4.34 Max: 18.76
Current: 7.06
0.02
18.76
Quick Ratio 7.06
IDRA's Quick Ratio is ranked higher than
68% of the 957 Companies
in the Global Biotechnology industry.

( Industry Median: 3.94 vs. IDRA: 7.06 )
Ranked among companies with meaningful Quick Ratio only.
IDRA' s Quick Ratio Range Over the Past 10 Years
Min: 0.02  Med: 4.34 Max: 18.76
Current: 7.06
0.02
18.76

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -63.70
IDRA's 3-Year Average Share Buyback Ratio is ranked lower than
89% of the 555 Companies
in the Global Biotechnology industry.

( Industry Median: -11.30 vs. IDRA: -63.70 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
IDRA' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -63.7  Med: -33.9 Max: -4.7
Current: -63.7
-63.7
-4.7

Valuation & Return

vs
industry
vs
history
Price/Net Cash 4.69
IDRA's Price/Net Cash is ranked higher than
61% of the 518 Companies
in the Global Biotechnology industry.

( Industry Median: 6.05 vs. IDRA: 4.69 )
Ranked among companies with meaningful Price/Net Cash only.
IDRA' s Price/Net Cash Range Over the Past 10 Years
Min: 2.02  Med: 6.7 Max: 141.33
Current: 4.69
2.02
141.33
Price/Net Current Asset Value 4.33
IDRA's Price/Net Current Asset Value is ranked higher than
64% of the 630 Companies
in the Global Biotechnology industry.

( Industry Median: 5.53 vs. IDRA: 4.33 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
IDRA' s Price/Net Current Asset Value Range Over the Past 10 Years
Min: 1.95  Med: 6.44 Max: 56.96
Current: 4.33
1.95
56.96
Price/Tangible Book 4.12
IDRA's Price/Tangible Book is ranked higher than
55% of the 785 Companies
in the Global Biotechnology industry.

( Industry Median: 4.33 vs. IDRA: 4.12 )
Ranked among companies with meaningful Price/Tangible Book only.
IDRA' s Price/Tangible Book Range Over the Past 10 Years
Min: 1.9  Med: 6.11 Max: 295
Current: 4.12
1.9
295
Price/Median PS Value 4.97
IDRA's Price/Median PS Value is ranked lower than
94% of the 589 Companies
in the Global Biotechnology industry.

( Industry Median: 0.93 vs. IDRA: 4.97 )
Ranked among companies with meaningful Price/Median PS Value only.
IDRA' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.04  Med: 1.17 Max: 115.75
Current: 4.97
0.04
115.75
Earnings Yield (Greenblatt) (%) -26.42
IDRA's Earnings Yield (Greenblatt) (%) is ranked lower than
76% of the 942 Companies
in the Global Biotechnology industry.

( Industry Median: -8.50 vs. IDRA: -26.42 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
IDRA' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: -29.33  Med: 5.4 Max: 11.1
Current: -26.42
-29.33
11.1

More Statistics

Revenue (TTM) (Mil) $1.11
EPS (TTM) $ -0.42
Beta2.77
Short Percentage of Float13.23%
52-Week Range $1.19 - 4.28
Shares Outstanding (Mil)147.65

Analyst Estimate

Dec16 Dec17 Dec18 Dec19
Revenue (Mil $) 1 1 1 38
EPS ($) -0.41 -0.39 -0.43 -0.35
EPS w/o NRI ($) -0.41 -0.39 -0.43 -0.35
EPS Growth Rate
(3Y to 5Y Estimate)
N/A
Dividends Per Share ($)
» More Articles for NAS:IDRA

Headlines

Articles On GuruFocus.com
Cowen & Co Remains Bullish on Celldex Therapeutics Following FDA 'Breakthrough' Approval Feb 24 2015 
Insiders Are Buying Idera Pharmaceuticals Sep 19 2013 

More From Other Websites
ETFs with exposure to Idera Pharmaceuticals, Inc. : December 9, 2016 Dec 09 2016
Idera Pharmaceuticals, Inc. :IDRA-US: Earnings Analysis: Q3, 2016 By the Numbers : December 8, 2016 Dec 08 2016
Why Idera Pharmaceuticals (IDRA) Could Be Positioned for a Surge Dec 02 2016
Idera Gets $15 Million for Shelved GI Drug (IDRA) Nov 29 2016
IDERA PHARMACEUTICALS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement,... Nov 28 2016
Idera Pharmaceuticals and Vivelix Pharmaceuticals, Ltd. Enter Into Exclusive License Agreement for... Nov 28 2016
Idera Pharmaceuticals Reports Translational Data Supporting the Mechanism of Action of Intratumoral... Nov 11 2016
Idera Pharmaceuticals Reports Translational Data Supporting the Mechanism of Action of Intratumoral... Nov 11 2016
Idera to Present at the Stifel 2016 Healthcare Conference Nov 10 2016
Idera Pharmaceuticals to Provide Multiple Presentations on Intratumoral IMO-2125 at the 2016 Society... Nov 09 2016
IDERA PHARMACEUTICALS, INC. Financials Nov 05 2016
IDERA PHARMACEUTICALS, INC. Files SEC form 10-Q, Quarterly Report Nov 01 2016
Idera reports 3Q loss Oct 28 2016
Idera reports 3Q loss Oct 28 2016
IDERA PHARMACEUTICALS, INC. Files SEC form 8-K, Results of Operations and Financial Condition,... Oct 28 2016
Idera Pharmaceuticals Reports Third Quarter 2016 Financial Results Oct 28 2016
Idera Pharmaceuticals Reports Third Quarter 2016 Financial Results Oct 28 2016
5 Stocks Insiders Love Right Now Oct 14 2016
5 Companies That Destroyed Shareholders This Past Week Oct 08 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)